0001564590-22-012069.txt : 20220329 0001564590-22-012069.hdr.sgml : 20220329 20220329083830 ACCESSION NUMBER: 0001564590-22-012069 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20220328 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220329 DATE AS OF CHANGE: 20220329 FILER: COMPANY DATA: COMPANY CONFORMED NAME: REGIONAL HEALTH PROPERTIES, INC CENTRAL INDEX KEY: 0001004724 STANDARD INDUSTRIAL CLASSIFICATION: LESSORS OF REAL PROPERTY, NEC [6519] IRS NUMBER: 815166048 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33135 FILM NUMBER: 22777540 BUSINESS ADDRESS: STREET 1: 454 SATELLITE BLVD STREET 2: SUITE 100 CITY: SUWANEE STATE: GA ZIP: 30024 BUSINESS PHONE: 678-869-5116 MAIL ADDRESS: STREET 1: 454 SATELLITE BLVD STREET 2: SUITE 100 CITY: SUWANEE STATE: GA ZIP: 30024 FORMER COMPANY: FORMER CONFORMED NAME: ADCARE HEALTH SYSTEMS, INC DATE OF NAME CHANGE: 20130530 FORMER COMPANY: FORMER CONFORMED NAME: ADCARE HEALTH SYSTEMS INC DATE OF NAME CHANGE: 19951208 8-K 1 rhe-8k_20220328.htm 8-K SPECIAL MEETING rhe-8k_20220328.htm
false 0001004724 GA 0001004724 2022-03-28 2022-03-28 0001004724 us-gaap:CommonStockMember 2022-03-28 2022-03-28 0001004724 us-gaap:SeriesAPreferredStockMember 2022-03-28 2022-03-28

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): March 28, 2022

 

Regional Health Properties, Inc.

(Exact Name of Registrant as Specified in Charter)

Georgia

 

001-33135

 

81-5166048

(State or Other Jurisdiction of

Incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

454 Satellite Boulevard, NW

Suite 100

Suwanee, Georgia 30024

(Address of Principal Executive Offices, and Zip Code)

 

(678) 869-5116

(Registrant’s telephone number, including area code)

Not applicable.

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☒

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, no par value

RHE

NYSE American

10.875% Series A Cumulative Redeemable Preferred Stock, no par value

RHE-PA

NYSE American

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

Item 5.07Submission of Matters to a Vote of Security Holders.

On March 28, 2022, Regional Health Properties, Inc., a Georgia corporation (the “Company” or “RHE”), convened its special meeting (the “Special Meeting”) of the holders of its 10.875% Series A Cumulative Redeemable Preferred Shares (the “Series A Preferred Stock”) and the holders of its common stock, no par value (the “Common Stock”). The Special Meeting was called to consider the proposals set forth in the Company’s definitive proxy statement/prospectus filed with the Securities and Exchange Commission (the “SEC”) on February 28, 2022 (the “Proxy Statement/Prospectus”) in connection with the Company’s offer to exchange (the “Exchange Offer”) any and all outstanding shares of the Series A Preferred Stock for newly issued shares of the Company’s 12.5% Series B Cumulative Redeemable Preferred Shares.

Below is a summary of the proposal that was submitted to the holders of Series A Preferred Stock and the holders of Common Stock for approval at the Special Meeting and a tabulation of the votes with respect to such proposal.

Adjournment Proposal

The holders of Series A Preferred Stock and the holders of Common Stock, voting together as a single class, approved the adjournment of the Special Meeting for the purpose of soliciting additional votes for the approval of the Required Proposals (as defined in the Proxy Statement/Prospectus) (the “Adjournment Proposal”). The Special Meeting will be adjourned to, and reconvene at, Sonesta Gwinnett Place Atlanta, located at 1775 Pleasant Hill Road, Duluth, Georgia, on Monday, May 2, 2022 at 10:00 a.m., Eastern Time. The voting results were as follows:

For

Against

Abstentions

Broker Non-Votes

2,273,045

182,724

25,971

—

 

Item 7.01Regulation FD Disclosure.

On March 29, 2022, the Company issued a press release announcing the convening and adjournment of the Special Meeting, the information for the reconvened Special Meeting and the extension of the Exchange Offer, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

The information provided pursuant to Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section, and shall not be incorporated by reference in any filing made by the Company under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), except to the extent expressly set forth by specific reference in any such filings.

Item 8.01Other Events.

Special Meeting

On March 28, 2022, the Company convened the Special Meeting. The Company announced, during the Special Meeting and prior to adjournment of the Special Meeting, that the Special Meeting will be reconvened on Monday, May 2, 2022 at 10:00 a.m., Eastern Time, at Sonesta Gwinnett Place Atlanta, located at 1775 Pleasant Hill Road, Duluth, Georgia. The record date for determination of the holders of Series A Preferred Stock and the holders of Common Stock entitled to notice of, and to vote at, the reconvened Special Meeting remains the close of business on February 24, 2022. The Company adjourned the Special Meeting pursuant to the Adjournment Proposal.

Any proxies previously submitted by the holders of Series A Preferred Stock and the holders of Common Stock with respect to the Special Meeting convened and adjourned on March 28, 2022 will continue to be counted. Such holders need not submit a new proxy in order for their votes to be counted. The holders of Series A Preferred Stock and the holders of Common Stock may revoke their proxies as set forth in the Proxy Statement/Prospectus.

Exchange Offer

On March 29, 2022, the Company announced that it is extending the expiration date for the Exchange Offer from 11:59 p.m., New York City time, on March 28, 2022 to 5:00 p.m., New York City time, on May 2, 2022 to allow additional time for the holders of Series A Preferred Stock to tender their shares of Series A Preferred Stock in the Exchange Offer.

2

 

Important Cautions Regarding Forward-Looking Statements

This Current Report on Form 8-K includes forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. Words such as “expects,” “intends,” “believes,” “anticipates,” “plans,” “likely,” “will,” “seeks,” “estimates” and variations of such words and similar expressions are intended to identify such forward-looking statements. Statements in this Current Report on Form 8-K regarding the timing of the reconvened Special Meeting and the Exchange Offer are forward-looking statements.

Forward-looking statements, by their nature, involve estimates, projections, goals, forecasts and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those projected or contemplated by our forward-looking statements due to various factors, including, among others: our dependence on the operating success of our operators; the significant amount of, and our ability to service, our indebtedness; covenants in our debt agreements that may restrict our ability to make investments, incur additional indebtedness and refinance indebtedness on favorable terms; the availability and cost of capital; our ability to raise capital through equity and debt financings or through the sale of assets; the effect of increasing healthcare regulation and enforcement on our operators and the dependence of our operators on reimbursement from governmental and other third-party payors; the relatively illiquid nature of real estate investments; the impact of litigation and rising insurance costs on the business of our operators; the impact on us of litigation relating to our prior operation of our healthcare properties; the effect of our operators declaring bankruptcy, becoming insolvent or failing to pay rent as due; the ability of any of our operators in bankruptcy to reject unexpired lease obligations and to impede our ability to collect unpaid rent or interest during the pendency of a bankruptcy proceeding and retain security deposits for the debtor’s obligations; our ability to find replacement operators and the impact of unforeseen costs in acquiring new properties; the impact of COVID-19 on our business and the business of our operators, including without limitation, the extent and duration of the COVID-19 pandemic, increased costs experienced by our operators in connection therewith, and the extent to which government support may be available to our operators to offset such costs and the conditions related thereto; and other factors discussed from time to time in our news releases, public statements and documents filed by us with the SEC from time to time, including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. These forward-looking statements and such risks, uncertainties and other factors speak only as of the date of this Current Report on Form 8-K, and we expressly disclaim any obligation or undertaking to update or revise any forward-looking statement contained herein, to reflect any change in our expectations with regard thereto or any other change in events, conditions or circumstances on which any such statement is based, except to the extent otherwise required by applicable law.

No Offer or Solicitation

This Current Report on Form 8-K is not intended to and shall not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made, except by means of a prospectus meeting the requirements of Section 10 of the Securities Act.

Additional Information about the Exchange Offer and Where to Find It

In connection with the proposed transaction, RHE filed with the SEC a registration statement on Form S-4 on June 1, 2021 (as amended on July 2, 2021, February 11, 2022 and February 22, 2022) that includes a proxy statement and that also constitutes a prospectus. The registration statement was declared effective by the SEC on February 25, 2022 at 9:00 a.m., Eastern Time. RHE filed the definitive proxy statement/prospectus in connection with the proposed transaction with the SEC. RHE commenced mailing the definitive proxy statement/prospectus to shareholders on or about February 28, 2022. RHE also filed with the SEC a joint statement on Schedule TO/13E-3 (the “Schedule TO/13E-3”) for the proposed transaction. The definitive proxy statement/prospectus and the Schedule TO/13E-3 will be supplemented to reflect the changes described in this press release. RHE intends to file other relevant documents with the SEC regarding the proposed transaction. This document is not a substitute for the definitive proxy statement/prospectus or registration statement or any other document that RHE may file with the SEC. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT, THE SCHEDULE TO/13E-3, THE DEFINITIVE PROXY STATEMENT/PROSPECTUS, AND ANY OTHER RELEVANT DOCUMENTS THAT MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT RHE AND THE PROPOSED TRANSACTION. Investors and security holders are able to obtain free copies of the registration statement, the Schedule TO/13E-3 and the definitive proxy statement/prospectus and all other documents containing important information about RHE and the proposed transaction, once such documents are filed with the SEC, including the definitive proxy statement/prospectus, through the website maintained by the SEC at www.sec.gov.  The proxy statement/prospectus included in the registration statement and additional copies of the proxy statement/prospectus will be available for free from RHE.

 

3

 

 

Participants in the Solicitation

RHE and certain of its directors and executive officers may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction. Information about the directors and executive officers of RHE, including a description of their direct or indirect interests, by security holdings or otherwise, is set forth in RHE’s proxy statement for its 2021 Annual Meeting of Shareholders, which was filed with the SEC on October 22, 2021, and RHE’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, which was filed with the SEC on February 22, 2022. Investors may obtain additional information regarding the interests of those persons and other persons who may be deemed participants in the proposed transaction by reading the definitive proxy statement/prospectus and other relevant materials to be filed with the SEC regarding the proposed transaction when such materials become available. Investors should read the definitive proxy statement/prospectus carefully before making any voting or investment decisions. You may obtain free copies of these documents from RHE using the sources indicated above.

 

 

Item 9.01Financial Statements and Exhibits.

 

(d)Exhibits

 

 

 

104               Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 


4

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date:

March 29, 2022

 

REGIONAL HEALTH PROPERTIES, INC.

 

 

 

 

 

 

 

/s/ Brent Morrison

 

 

 

Brent Morrison

 

 

 

Chief Executive Officer and President

 

 

5

 EX-99.1 2 rhe-ex991_24.htm EX-99.1 PRESS RELEASE 3.29.2022 rhe-ex991_24.htm

Exhibit 99.1

 

 

Regional Health Properties, Inc. Announces Convening and Adjournment of Special Meeting, Information for Reconvened Special Meeting and Extension of Exchange Offer

ATLANTA, GA, March 29, 2022 — Regional Health Properties, Inc. (NYSE American: RHE) (NYSE American: RHE-PA) (“RHE” or the “Company”), a self-managed healthcare real estate investment company that invests primarily in real estate purposed for senior living and long-term care, convened its special meeting (the “Special Meeting”) of the holders of its 10.875% Series A Cumulative Redeemable Preferred Shares (the “Series A Preferred Stock”) and holders of its common stock, no par value (the “Common Stock”), on March 28, 2022. At the Special Meeting, the holders of Series A Preferred Stock and the holders of Common Stock, voting together as a single class, approved the adjournment of the Special Meeting for the purpose of soliciting additional votes for the approval of the Required Proposals (as defined in the Proxy Statement/Prospectus (as defined herein), and the Special Meeting was adjourned.

The Special Meeting will be reconvened on Monday, May 2, 2022 at 10:00 a.m., Eastern Time, at Sonesta Gwinnett Place Atlanta, located at 1775 Pleasant Hill Road, Duluth, Georgia. The record date for determination of the holders of Series A Preferred Stock and the holders of Common Stock entitled to notice of, and to vote at, the reconvened Special Meeting remains the close of business on February 24, 2022.

Any proxies previously submitted by the holders of Series A Preferred Stock and the holders of Common Stock with respect to the Special Meeting convened and adjourned on March 28, 2022 will continue to be counted. Such holders need not submit a new proxy for their votes to be counted. The holders of Series A Preferred Stock and the holders of Common Stock may revoke their proxies as set forth in the Proxy Statement/Prospectus.

As previously announced, the Company commenced an offer to exchange (the “Exchange Offer”) any and all of its outstanding Series A Preferred Stock for newly issued shares of the Company’s 12.5% Series B Cumulative Redeemable Preferred Shares. The Company is extending the expiration date for the Exchange Offer from 11:59 p.m., New York City time, on March 28, 2022 to 5:00 p.m., New York City time, on May 2, 2022 to allow additional time for the holders of Series A Preferred Stock to tender their shares of Series A Preferred Stock in the Exchange Offer. As of 11:59 p.m., New York City time, on March 28, 2022, 1,945,379 shares of Series A Preferred Stock had been properly tendered (and not validly withdrawn) in the Exchange Offer.

Morrow Sodali LLC is acting as the Information Agent in connection with the Exchange Offer and as the Proxy Solicitor in connection with the Special Meeting, and Continental Stock Transfer & Trust Company, our transfer agent, is acting as the Exchange Agent in connection with the Exchange Offer.

The complete terms and conditions of the Exchange Offer are set forth in the Proxy Statement/Prospectus (as it may be supplemented and amended from time to time, the “Proxy

 

 

Statement/Prospectus”) and the related Letter of Transmittal (the “Letter of Transmittal”) that are filed with the U.S. Securities and Exchange Commission (the “SEC”) under cover of Schedule TO/13E-3 and were sent to holders of the existing Series A Preferred Stock and Common Stock, as applicable. The Proxy Statement/Prospectus and the notice of the Special Meeting were mailed to holders of record of Series A Preferred Stock and holders of record of Common Stock as of the close of business on February 24, 2022 beginning on or about February 28, 2022. You may obtain free copies of the Proxy Statement/Prospectus, the related Letter of Transmittal and all other documents containing important information about RHE and the Exchange Offer through the SEC’s website at www.sec.gov or by contacting the Information Agent and Proxy Solicitor, Morrow Sodali LLC, at (203) 658-9400 for banks and brokers (collect) and (800) 662-5200 for all other callers (toll free). You will not be charged for any of these documents that you request.

About Regional Health Properties

Regional Health Properties, Inc. (NYSE American: RHE) (NYSE American: RHE-PA) is the successor to AdCare Health Systems, Inc., and is a self-managed healthcare real estate investment company that invests primarily in real estate purposed for senior living and long-term healthcare through facility lease and sub-lease transactions, and operation of such real estate when required.

The Company currently owns, leases, manages for third parties, and operates, 24 facilities. The Company: (i) leased 10 skilled nursing facilities (“SNFs”) (which the Company owns); (ii) subleased eight SNFs (which the Company leases) to third-party tenants; (iii) operated one SNF, as of January 1, 2021, previously subleased (which the Company leases); (iv) leased two assisted living facilities (which the Company owns) to third-party tenants; and (v) managed, on behalf of third-party owners, two SNFs and one independent living facility.


Important Cautions Regarding Forward-Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “expects,” “intends,” “believes,” “anticipates,” “plans,” “likely,” “will,” “seeks,” “estimates” and variations of such words and similar expressions are intended to identify such forward-looking statements. Statements in this press release regarding the timing of the reconvened Special Meeting and the Exchange Offer are forward-looking statements.

Forward-looking statements, by their nature, involve estimates, projections, goals, forecasts and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those projected or contemplated by our forward-looking statements due to various factors, including, among others: our dependence on the operating success of our operators; the significant amount of, and our ability to service, our indebtedness; covenants in our debt agreements that may restrict our ability to make investments, incur additional indebtedness and refinance indebtedness on favorable terms; the availability and cost of capital; our ability to raise capital through equity and debt financings or through the sale of assets; the effect of increasing healthcare regulation and enforcement on our operators and the dependence of our operators on reimbursement from governmental and other third-party payors; the relatively illiquid nature of real estate investments; the impact of litigation and rising insurance

 

 

costs on the business of our operators; the impact on us of litigation relating to our prior operation of our healthcare properties; the effect of our operators declaring bankruptcy, becoming insolvent or failing to pay rent as due; the ability of any of our operators in bankruptcy to reject unexpired lease obligations and to impede our ability to collect unpaid rent or interest during the pendency of a bankruptcy proceeding and retain security deposits for the debtor’s obligations; our ability to find replacement operators and the impact of unforeseen costs in acquiring new properties; the impact of COVID-19 on our business and the business of our operators, including without limitation, the extent and duration of the COVID-19 pandemic, increased costs experienced by our operators in connection therewith, and the extent to which government support may be available to our operators to offset such costs and the conditions related thereto; and other factors discussed from time to time in our news releases, public statements and documents filed by us with the SEC from time to time, including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. These forward-looking statements and such risks, uncertainties and other factors speak only as of the date of this press release, and we expressly disclaim any obligation or undertaking to update or revise any forward-looking statement contained herein, to reflect any change in our expectations with regard thereto or any other change in events, conditions or circumstances on which any such statement is based, except to the extent otherwise required by applicable law.

No Offer or Solicitation

This communication is not intended to and shall not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made, except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended.

Additional Information about the Exchange Offer and Where to Find It

In connection with the proposed transaction, RHE filed with the SEC a registration statement on Form S-4 on June 1, 2021 (as amended on July 2, 2021, February 11, 2022 and February 22, 2022) that includes a proxy statement and that also constitutes a prospectus. The registration statement was declared effective by the SEC on February 25, 2022 at 9:00 a.m., Eastern Time. RHE filed the definitive proxy statement/prospectus in connection with the proposed transaction with the SEC. RHE commenced mailing the definitive proxy statement/prospectus to shareholders on or about February 28, 2022. RHE also filed with the SEC a joint statement on Schedule TO/13E-3 (the “Schedule TO/13E-3”) for the proposed transaction. The definitive proxy statement/prospectus and the Schedule TO/13E-3 will be supplemented to reflect the changes described in this press release. RHE intends to file other relevant documents with the SEC regarding the proposed transaction. This document is not a substitute for the definitive proxy statement/prospectus or registration statement or any other document that RHE may file with the SEC. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT, THE SCHEDULE TO/13E-3, THE DEFINITIVE PROXY STATEMENT/PROSPECTUS, AND ANY OTHER RELEVANT DOCUMENTS THAT MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT RHE AND THE

 

 

PROPOSED TRANSACTION. Investors and security holders are able to obtain free copies of the registration statement, the Schedule TO/13E-3 and the definitive proxy statement/prospectus and all other documents containing important information about RHE and the proposed transaction, once such documents are filed with the SEC, including the definitive proxy statement/prospectus, through the website maintained by the SEC at www.sec.gov. The proxy statement/prospectus included in the registration statement and additional copies of the proxy statement/prospectus will be available for free from RHE.

Participants in the Solicitation

RHE and certain of its directors and executive officers may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction. Information about the directors and executive officers of RHE, including a description of their direct or indirect interests, by security holdings or otherwise, is set forth in RHE’s proxy statement for its 2021 Annual Meeting of Shareholders, which was filed with the SEC on October 22, 2021, and RHE’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, which was filed with the SEC on February 22, 2022. Investors may obtain additional information regarding the interests of those persons and other persons who may be deemed participants in the proposed transaction by reading the definitive proxy statement/prospectus and other relevant materials to be filed with the SEC regarding the proposed transaction when such materials become available. Investors should read the definitive proxy statement/prospectus carefully before making any voting or investment decisions. You may obtain free copies of these documents from RHE using the sources indicated above.

Company Contact

Brent Morrison

Chief Executive Officer and President

Regional Health Properties, Inc.

Tel (678) 368-4402

brent.morrison@regionalhealthproperties.com

Investor Relations
Brett Maas

Managing Partner
Hayden IR

Tel (646) 536-7331
brett@haydenir.com

 

 

 GRAPHIC 3 gb3zlnw25zbv000001.jpg GRAPHIC begin 644 gb3zlnw25zbv000001.jpg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end EX-101.SCH 4 rhe-20220328.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.DEF 5 rhe-20220328_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 6 rhe-20220328_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Information [Table] Document Information [Table] Class of Stock Statement Class Of Stock [Axis] Class of Stock Class Of Stock [Domain] Common Stock Common Stock [Member] 10.875% Series A Cumulative Redeemable Preferred Stock Series A Preferred Stock [Member] Document Information [Line Items] Document Information [Line Items] Document Type Document Type Amendment Flag Amendment Flag Entity Central Index Key Entity Registrant Name Entity Registrant Name Document Period End Date Document Period End Date Entity Emerging Growth Company Entity Emerging Growth Company Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Title of 12(b) Security Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name EX-101.PRE 7 rhe-20220328_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information
Mar. 28, 2022
Document Information [Line Items]  
Document Type 8-K
Amendment Flag false
Entity Central Index Key 0001004724
Entity Registrant Name Regional Health Properties, Inc.
Document Period End Date Mar. 28, 2022
Entity Emerging Growth Company false
Entity File Number 001-33135
Entity Incorporation, State or Country Code GA
Entity Tax Identification Number 81-5166048
Entity Address, Address Line One 454 Satellite Boulevard, NW
Entity Address, Address Line Two Suite 100
Entity Address, City or Town Suwanee
Entity Address, State or Province GA
Entity Address, Postal Zip Code 30024
City Area Code 678
Local Phone Number 869-5116
Written Communications true
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Common Stock  
Document Information [Line Items]  
Title of 12(b) Security Common Stock, no par value
Trading Symbol RHE
Security Exchange Name NYSEAMER
10.875% Series A Cumulative Redeemable Preferred Stock  
Document Information [Line Items]  
Title of 12(b) Security 10.875% Series A Cumulative Redeemable Preferred Stock, no par value
Trading Symbol RHE-PA
Security Exchange Name NYSEAMER
XML 9 rhe-8k_20220328_htm.xml IDEA: XBRL DOCUMENT 0001004724 2022-03-28 2022-03-28 0001004724 us-gaap:CommonStockMember 2022-03-28 2022-03-28 0001004724 us-gaap:SeriesAPreferredStockMember 2022-03-28 2022-03-28 false 0001004724 GA 8-K 2022-03-28 Regional Health Properties, Inc. 001-33135 81-5166048 454 Satellite Boulevard, NW Suite 100 Suwanee GA 30024 678 869-5116 true false false false Common Stock, no par value RHE NYSEAMER 10.875% Series A Cumulative Redeemable Preferred Stock, no par value RHE-PA NYSEAMER false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 3 23 1 false 2 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://regionalhealthproperties.com/20220328/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports rhe-8k_20220328.htm rhe-20220328.xsd rhe-20220328_def.xml rhe-20220328_lab.xml rhe-20220328_pre.xml rhe-ex991_24.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "rhe-8k_20220328.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 3, "dts": { "definitionLink": { "local": [ "rhe-20220328_def.xml" ] }, "inline": { "local": [ "rhe-8k_20220328.htm" ] }, "labelLink": { "local": [ "rhe-20220328_lab.xml" ] }, "presentationLink": { "local": [ "rhe-20220328_pre.xml" ] }, "schema": { "local": [ "rhe-20220328.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 30, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 2, "nsprefix": "rhe", "nsuri": "http://regionalhealthproperties.com/20220328", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "rhe-8k_20220328.htm", "contextRef": "C_0001004724_20220328_20220328", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://regionalhealthproperties.com/20220328/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "rhe-8k_20220328.htm", "contextRef": "C_0001004724_20220328_20220328", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 2, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regionalhealthproperties.com/20220328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regionalhealthproperties.com/20220328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]", "terseLabel": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regionalhealthproperties.com/20220328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]", "terseLabel": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regionalhealthproperties.com/20220328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regionalhealthproperties.com/20220328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regionalhealthproperties.com/20220328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regionalhealthproperties.com/20220328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regionalhealthproperties.com/20220328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regionalhealthproperties.com/20220328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regionalhealthproperties.com/20220328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regionalhealthproperties.com/20220328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regionalhealthproperties.com/20220328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regionalhealthproperties.com/20220328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regionalhealthproperties.com/20220328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regionalhealthproperties.com/20220328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regionalhealthproperties.com/20220328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regionalhealthproperties.com/20220328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regionalhealthproperties.com/20220328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regionalhealthproperties.com/20220328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regionalhealthproperties.com/20220328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regionalhealthproperties.com/20220328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regionalhealthproperties.com/20220328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regionalhealthproperties.com/20220328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regionalhealthproperties.com/20220328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regionalhealthproperties.com/20220328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class Of Stock [Domain]", "terseLabel": "Class of Stock" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regionalhealthproperties.com/20220328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regionalhealthproperties.com/20220328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series A Preferred Stock [Member]", "terseLabel": "10.875% Series A Cumulative Redeemable Preferred Stock" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regionalhealthproperties.com/20220328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Class Of Stock [Axis]", "terseLabel": "Class of Stock" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regionalhealthproperties.com/20220328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 17 0001564590-22-012069-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-22-012069-xbrl.zip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

4 M " 6P+ !R:&4M,C R,C S,CA?;&%B+GAM;%!+ 0(4 Q0 ( ,Y$?53) MJ6)DV 4 "\Z 4 " 1,4 !R:&4M,C R,C S,CA?<')E M+GAM;%!+ 0(4 Q0 ( ,Y$?52AC%C)?"( *?U 3 " M 1T: !R:&4M.&M?,C R,C S,C@N:'1M4$L! A0#% @ SD1]5&7(7>RT M%0 &V4 ! ( !RCP ')H92UE>#DY,5\R-"YH=&U02P4& 2 8 !@"# 0 K%( end